A61K 40/4258
Gangliosides
Official title: {Gangliosides, e.g. GM2, GD2 or GD3}
A61K40/4258 (Gangliosides) appears on 55 US grants and 178 published applications in this corpus.
Search patents in A61K- Granted patents
- 55
- Published applications
- 178
- Assignees
- 78
- Inventors
- 319
- Latest grant
- 8 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1989 | 1 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 0 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 0 | 0 |
| 1997 | 0 | 0 |
| 1998 | 1 | 0 |
| 1999 | 0 | 0 |
| 2000 | 0 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 2 |
| 2003 | 0 | 1 |
| 2004 | 0 | 0 |
| 2005 | 0 | 0 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 0 | 0 |
| 2010 | 0 | 0 |
| 2011 | 0 | 1 |
| 2012 | 0 | 0 |
| 2013 | 0 | 1 |
| 2014 | 0 | 6 |
| 2015 | 0 | 0 |
| 2016 | 3 | 4 |
| 2017 | 1 | 7 |
| 2018 | 1 | 6 |
| 2019 | 2 | 9 |
| 2020 | 2 | 16 |
| 2021 | 2 | 22 |
| 2022 | 5 | 21 |
| 2023 | 8 | 11 |
| 2024 | 6 | 33 |
| 2025 | 14 | 24 |
| 2026 | 9 | 14 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Compositions and methods for inhibiting T cell exhaustion8 Sep 2026US 12,729,245 B2The Board of Trustees of the Leland Stanford Junior University
- Methods and compositions for chimeric antigen receptor targeting cancer cells1 Sep 2026US 12,721,892 B2The University of North Carolina at Chapel Hill
- MiR200c-EpCAM axis reprogramed immune cells for enhanced anti-tumor function9 Jun 2026US 12,648,963 B2Memorial Hospital for Cancer and Allied Diseases
- Armed dual CAR-T compositions and methods for cancer immunotherapy2 Jun 2026US 12,643,933 B2Simcere Innovation, Inc.
- Method for gene transfer into gamma-delta type T cell26 May 2026US 12,637,658 B2Mie University
- Modulation of b-cell translocation gene 1 (btg1) for use in adoptive cell therapy1 Oct 2026US 2026/0294968 A1Baylor College of Medicine
- Method for the production of bi-functional cells to treat neoplasia1 Oct 2026US 2026/0297162 A1Eir Biotherapies Srl
- SIRPalpha Knockout iPSC-derived and CAR-comprising Macrophages with Enhanced Anti-tumor Activity24 Sep 2026US 2026/0284104 A1Wisconsin Alumni Research Foundation
- Gd2-specific chimeric antigen receptor effector cells for use in the treatment of solid tumors, possibly in combination with enhancer of zeste homolog 2 (ezh2) inhibitors10 Sep 2026US 2026/0265408 A1
- Microenvironment actuated t-cells and uses thereof20 Aug 2026US 2026/0242732 A1
Most cited
By later US patents
- Method for proliferation of antigen-specific T cells54US 9,476,028 B2Immunicum AB · 2016
- Immunotherapy of cancer using genetically engineered GD2-specific T cells16US 9,493,740 B2Baylor College of Medicine · 2016
- Methods for inducing partial apoptosis using caspase polypeptides16US 9,913,882 B2Bellicum Pharmaceuticals, Inc. · 2018
- Method for proliferation of antigen-specific T cells11US 9,789,174 B2Immunicum AB · 2017
- Chimeric antigen receptor (CAR) targeting multiple antigens, compositions and methods of use thereof5US 11,173,179 B2iCell Gene Therapeutics Inc. · 2021